You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 26, 2024

Patent Applications for venlafaxine besylate


✉ Email this page to a colleague

« Back to Dashboard


US Patent Applications for venlafaxine besylate

US Patent Application Patent No. Title Patent Filing Date Patent Application Status Status Updated
⤷  Sign Up ⤷  Sign Up LOW WATER-SOLUBLE VENLAFAXINE SALTS 2003-03-27 Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362 2008-03-24
⤷  Sign Up ⤷  Sign Up Venlafaxine base 2003-03-27 Abandoned -- Failure to Respond to an Office Action 2006-03-06
⤷  Sign Up ⤷  Sign Up VENLAFAXINE BESYLATE 2003-03-27 Patented Case 2004-03-18
>US Patent Application >Patent No. >Title >Patent Filing Date >Patent Application Status >Status Updated

WIPO Patent Applications for venlafaxine besylate

WIPO Patent Application Title Patent Filing Date
⤷  Sign Up
⤷  Sign Up
>WIPO Patent Application >Title >Patent Filing Date

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.